Susan Bro Quotes (4 Quotes)

In response to inquiries, including from Congress, we are clarifying our position on the science.

Because these liver problems are significant and somewhat idiosyncratic or unpredictable, the FDA is evaluating the use of this medicine in both the U.S. and abroad where it is used and marketed to determine whether additional warning guidance is merited.

We are examining the ruling and have not made a decision yet as to what are next steps will be.

We are continuing to work with the company to see that all of the issues that have been previously identified are being addressed. It's premature to draw any conclusions from this step in the process. The re-inspection process is still under way and final conclusions have not been determined.